Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: Results from the Interfant-99 Study

Blood

Volumn 116, Issue 15, 2010, Pages 2644-2650

  Mann, Georg ^a   Attarbaschi, Andishe ^a   Schrappe, Martin ^b   De Lorenzo, Paola ^c   Peters, Christina ^a   Hann, Ian ^d   De Rossi, Giulio ^e   Felice, Maria ^f   Lausen, Birgitte ^g,s,t,u,v   LeBlanc, Thierry ^h   Szczepanski, Tomasz ⁱ   Ferster, Alina ^j,w,x   Janka Schaub, Gritta ^k   Rubnitz, Jeffrey ^l   Silverman, Lewis B ^m   Stary, Jan ⁿ   Campbell, Myriam ^o   Li, Chi Kong ^p   Suppiah, Ram ^q   Biondi, Andrea ^e   Vora, Ajay ^d   Valsecchi, Maria Grazia ^c   Pieters, Rob ^r   more..

^a Berlin Frankfurt Münster Group   (Austria)

^b Berlin Frankfurt Munster Study Group   (Germany)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d United Kingdom Children's Cancer Study Group   (United Kingdom)

^e Associazione Italiana Ematologia Oncologia Pediatrica   (Italy)

^f Argentinean Group of Pediatric Hematology and Oncology   (Argentina)

^g Nordic Society of Pediatric Hematology and Oncology   (Norway)

^h French Acute Lymphoblastic Leukemia Study Group   (France)

ⁱ Polish Pediatric Leukemia and Lymphoma Study Group   (Poland)

^j Children's Leukemia Group   (France)

^k St Jude Children's Research Hospital ^*  (Germany)

^l ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^m DANA FARBER CANCER INSTITUTE   (United States)

ⁿ Czech Pediatric Haematology   (Czech Republic)

^o Programa Infantil Nacional de Drogas Antineoplásicas PINDA   (Chile)

^p Hong Kong Pediatric Hematology and Oncology Study Group   (Hong Kong)

^q Australian and New Zealand Children's Haematology and Oncology Study Group   (Australia)

^r SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^s Nordic Society of Pediatric Hematology and Oncology   (Sweden)

^t Nordic Society of Pediatric Hematology and Oncology   (Denmark)

^u Nordic Society of Pediatric Hematology and Oncology   (Finland)

^v Nordic Society of Pediatric Hematology and Oncology   (Iceland)

^w Children's Leukemia Group   (Belgium)

^x Children's Leukemia Group   (Portugal)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; MIXED LINEAGE LEUKEMIA PROTEIN; PREDNISOLONE; PREDNISONE; TIOGUANINE; VINCRISTINE; MLL PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG MEGADOSE; GENE; GRAFT VERSUS HOST REACTION; GROUPS BY AGE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INFANT; LEUKOCYTE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; RISK REDUCTION; TREATMENT FAILURE; TREATMENT RESPONSE; AGE; BLOOD; CONTROLLED STUDY; GENE REARRANGEMENT; GENETICS; LEUKOCYTE COUNT; MULTICENTER STUDY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

AGE FACTORS; DISEASE-FREE SURVIVAL; GENE REARRANGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKOCYTE COUNT; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77957949594     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-273532     Document Type: Article

References (31)

1. Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. Blood. 2000;96(1):24-33.
2. Borkhardt A, Wuchter C, Viehmann S, et al. Infant acute lymphoblastic leukemia: combined cytogenetic, immunophenotypical and molecular analysis of 77 cases. Leukemia. 2002;16(9):1685-1690.
3. Mann G, Cazzaniga G, van der Velden VH, et al. Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: the 'big sister' of the infant disease? Leukemia. 2007;21(4):642-646.
4. Dördelmann M, Reiter A, Borkhardt A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 1999;94(4):1209-1217. (Pubitemid 29380401)
5. Silverman LB. Acute lymphoblastic leukemia in infancy. Pediatr Blood Cancer. 2007;49(7 suppl):1070-1073.
6. Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomized trial. Lancet. 2007;370(9583):240-250. (Pubitemid 47082422)
7. Meyer C, Schneider B, Jakob S, et al. The MLL recombinome of acute leukemias. Leukemia. 2006;20(5):777-784.
8. Hunger SP, Loh KM, Baker KS, Schultz KR. Controversies of and unique issues in hematopoietic cell transplantation for infant leukemia. Biol Blood Marrow Transplant. 2009;15(1 suppl):79-83.
9. Leung W, Hudson M, Zhu Y, et al. Late effects in survivors of infant leukemia. Leukemia. 2000;14(7):1185-1190. (Pubitemid 30445023)
10. Tomizawa D, Koh K, Sato T, et al. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia. 2007;21(11):2258-2263. (Pubitemid 350011697)
11. Pui CH, Chessells JM, Camitta B, et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia. 2003;17(4):700-706. (Pubitemid 36519366)
12. Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002;359(9321):1909-1915.
13. van der Does-van den Berg A, Bartram CR, Basso G, et al. Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the "BFM Family" Cooperative Group. Med Pediatr Oncol. 1992;20(6):497-505.
14. Attarbaschi A, Mann G, König M, et al. Mixed lineage leukemia-rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity. Clin Cancer Res. 2006;12(10):2988-2994. (Pubitemid 43837342)
15. De Lorenzo P, Antolini L, Valsecchi MG. Evaluation of alternative prognostic stratifications by prediction accuracy measures on individual survival with application to childhood leukaemia. Eur J Cancer. 2009;45(8):1432-1437.
16. Balduzzi A, Valsecchi MG, Uderzo C, et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomization in an international prospective study. Lancet. 2005;366(9486):635-642. (Pubitemid 41176015)
17. Schrauder A, Reiter A, Gadner H, et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol. 2006;24(36):5742-5749. (Pubitemid 46631317)
18. Jacobsohn DA, Hewlett B, Morgan E, Tse W, Duerst RE, Kletzel M. Favorable outcome for infant acute lymphoblastic leukemia after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(12):999-1005. (Pubitemid 41754718)
19. Sanders JE, Im HJ, Hoffmeister PA, et al. Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. Blood. 2005;105(9):3749-3756. (Pubitemid 40628227)
20. Marco F, Bureo E, Ortega JJ, et al. High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support: Groupo Espanol de Trasplante de Medula Osea en Ninos. J Clin Oncol. 2000;18(18):3256-3261.
21. Kosaka Y, Koh K, Kinukawa N, et al. Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood. 2004;104(12):3527-3534. (Pubitemid 39564423)
22. Eapen M, Rubinstein P, Zhang MJ, et al. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol. 2006;24(1):145-151. (Pubitemid 46630506)
23. Dreyer ZE, Dinndorf P, Sather H, et al. Hematopoietic stem cell transplant (HSCT) versus intensive chemotherapy in infant acute lymphoblastic leukemia [abstract]. J Clin Oncol. 2007;25(suppl ASCO Meeting Abstracts):9514.
24. Chessells JM, Harrison CJ, Watson SL, Vora AJ, Richards SM. Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999. Br J Haematol. 2002;117(2):306-314.
25. Perkins JL, Kunin-Batson AS, Youngren NM, et al. Long-term follow-up of children who underwent hematopoeitic cell transplant (HCT) for AML or ALL at less than 3 years of age. Pediatr Blood Cancer. 2007;49(7):958-963.
26. Van der Velden VH, Corral L, Valsecchi MG, et al. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia. 2009;23(6):1073-1079.
27. van der Velden VH, Panzer-Grümayer ER, Cazzaniga G, et al. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multicenter setting. Leukemia. 2007;21(4):706-713. (Pubitemid 46444554)
28. Stam RW, den Boer ML, Schneider P, et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood. 2005;106(7):2484-2490. (Pubitemid 41510823)
29. Kreyenberg H, Eckert C, Yarkin Y, et al. Immunoglobulin and T-cell receptor gene rearrangements as PCR-based targets are stable markers for monitoring minimal residual disease in acute lymphoblastic leukemia after stem cell transplantation. Leukemia. 2009;23(7):1355-1358.
30. Pulsipher MA, Bader P, Klingebiel T, Cooper LJ. Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biol Blood Marrow Transplant. 2009;15(1 suppl):62-71.
31. Stumpel DJ, Schneider P, van Roon EH, et al. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood. 2009;114(27):5490-5498.